Abstract
Public health control strategies, such as lockdown, seem to be effective in reducing the spread of the pandemic, but are ineffective as a whole since lockdown is responsible of global economic crisis and badly lived by the majority of children and adults who have developed mental health disorders and familial problems as well. Thus, the development of a vaccine against COVID-19 is needed to control this disease. We have developed a discrete age-structured model and followed the Moroccan vaccination program to assess the impact of booster vaccination targeting Moroccan adults against COVID-19. Using the derived model, we estimated some relevant model parameters related to COVID-19 using collected cumulative mortality and reported Moroccan data. A control reproduction number Rc, which determines the necessary level of vaccine uptake that lead to COVID-19 eradication is determined. Furthermore, a herd immunity threshold above which the population can be protected from COVID-19 infection is derived. Analyzing the model, sufficient and necessary conditions for the eradication of the disease are obtained as well. Next, we perform numerical simulations to study the impact of several uptake levels of the potential vaccine on the persistence and the extinction of COVID-19 pandemic. Our results show that the COVID-19 is expected to last past 2021 in the absence of a vaccination program. Moreover, a vaccination of the adult population at rate 0.6% per day needs at least 67% of vaccine efficacy and 90% of immunogenicity rate to eradicate the disease. Using Sinopharm vaccine, the herd immunity can be achieved when about half of Moroccan adult population is immunized against the COVID-19. However, using Oxford-Astrazeneca vaccine, less than 60% of adult population must be immunized against the disease to achieve the herd immunity. Finally, if vaccine efficacy is about 80% and the immunogenicity is about 50% then vaccinating adults at rate of 0.6% per day could protect roughly 22% of children from COVID-19 infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
